With R&D flops mounting, Eli Lilly likely to slash budget, analysts say

Tracy Staton The litany of clinical trial failures for Eli Lilly's pipeline programs is likely to force the company to start carving up its R&D budget as the pharma giant enters ...

FDA experts vote against expansion of Amarin’s Vascepa

Eric Palmer An FDA advisory panel is against extending the use of Amarin's fish-oil drug Vascepa with a cholesterol-lowering statin to reduce the risk of coronary disease; they ...

High stakes

joshua.slatko With the Zyprexa era over, Lilly is betting big on its ability to innovate in the pipeline. By Joshua Slatko joshua.slatko@ubm.com This past year was the first of three ...

AstraZeneca, Amgen Crohn’s drug runs into PhII ‘logistical’ snafu

John Carroll One of the programs involved in AstraZeneca's $ 50 million bid to collaborate with Amgen on the development of a slate of biologics has run into a snafu of some sort. ...

Activist investor says XenoPort should bag Horizant, and its CEO, too

Tracy Staton GlaxoSmithKline gave up on the restless leg syndrome drug Horizant earlier this year. XenoPort, which developed the drug, may be next. A leading investor in the small company ...

Cancer immunotherapies set to storm onto the market, analysts say

Tracy Staton Over the past year the excitement in biopharma R&D circles about the therapeutic punch of cancer immunotherapies has reached fever pitch, and the intense ...

Study: Online Consumer Health Engagement Expanding

mia.burns By Mia Burns (mia.burns@ubm.com) Consumer use of health websites and other online tools to collect information about conditions and treatments is not a new trend, but now ...

Billionaire-backed immatics bags $46M to wrap cancer vaccine PhIII

Damian Garde Armed with a promising data and the support of biotech billionaire Dietmar Hopp, Germany's immatics now has the cash to get its cancer vaccine past the goal line, closing ...

How do U.S. drugs come to cost more? Let us count the ways

Tracy Staton Why the disparity in drug prices? It's a question asked repeatedly, and the specific answers are multifarious and complex.  FiercePharma News

A sweet spot to be in

chris.truelove by Christiane Truelove chris.truelove@ubm.com For Novo Nordisk in 2012, laser-focused strategy paid off once again with double-digit growth, despite the continuing difficulties ...

Aratana adds pet therapies in $38M deal to acquire Vet

John Carroll Aratana Therapeutics has struck a deal to buy San Diego-based Vet Therapeutics, adding new pet therapies to its pipeline for $ 30 million in cash, a chunk of stock, a ...

Sanofi nabs OTC nod for Nasacort amid consumer healthcare push

Carly Helfand It's a win for the company, whose consumer healthcare strategy focuses on switching drugs over from prescription status. And it sets a regulatory precedent for other ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS